EGLN1 and chronic kidney disease: To study the role of targeting PHD2 in platelet aggregation, we used three PHD2 inhibitors, Dap, Rox, and Vad, which have been clinically approved for treating symptomatic anemia in chronic kidney disease patients32, 33, 34.